文献速递泌尿男性生殖肿瘤

在活检初治患者中基于多参数MRI使用前列腺系统穿刺与靶向穿刺(MRI-FIRST):一项前瞻性、多中心、配对诊断研究

Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.
PubMed 文献 · Lancet Oncol · 2018-11-21

这项在法国16个中心开展的前瞻性配对诊断研究纳入275例活检初治患者,比较系统穿刺与基于多参数MRI的靶向穿刺对临床显著前列腺癌(ISUP分级分组≥2)的检出。系统穿刺检出率29.9%与靶向穿刺32.3%无显著差异(p=0.38),但两种方法联合可提高检出,且多参数MRI似乎不能避免系统穿刺。

要点

  • 系统穿刺检出临床显著前列腺癌29.9%(95%CI 24.3-36.0),靶向穿刺32.3%(26.5-38.4),差异无统计学显著(p=0.38)。
  • 若不做系统穿刺,5.2%(95%CI 2.8-8.7)患者的临床显著前列腺癌会被漏诊;若不做靶向穿刺,漏诊率为7.6%(4.6-11.6)。
  • 活检后报告4例3级不良事件:3例前列腺炎、1例尿潴留伴血尿。

核心结论

  • 系统穿刺与靶向穿刺对ISUP分级分组≥2前列腺癌的检出无差异,但两种方法联合可提高检出,两者均有实质性附加价值。
  • 活检前进行多参数MRI可提高活检初治患者临床显著前列腺癌的检出,但似乎不能避免系统穿刺的必要性。

研究设计与样本

  • 前瞻性、多中心、配对诊断研究,在法国16个中心开展。
  • 纳入年龄18-75岁、前列腺特异性抗原≤20 ng/mL、分期T2c或更低的前列腺癌患者,均为首次前列腺活检前转诊行多参数MRI,MRI与活检计划间隔小于3个月。
  • 系统穿刺由对多参数MRI结果设盲的操作者完成,取12个系统针芯及最多2个针对低回声病灶的针芯;同一患者中另一操作者基于多参数MRI对Likert评分≥3的病灶行靶向穿刺,最多2个病灶、每病灶3个针芯;多参数MRI阴性(Likert≤2)者仅行系统穿刺。
  • 主要结局为国际泌尿病理学会(ISUP)分级分组≥2的临床显著前列腺癌(csPCa-A)检出,分析人群为同时接受系统与靶向穿刺且两者结果均可用于病理中心复核的患者,包括方案偏离者。
  • 研究注册号NCT02485379,已停止纳入新参与者。

主要发现

  • 2015年7月15日至2016年8月11日共纳入275例患者,24例(9%)被排除分析。
  • 251例分析患者中53例(21%)多参数MRI阴性(Likert≤2)。
  • 251例中94例(37%)检出csPCa-A;其中13例(14%)仅由系统穿刺诊断,19例(20%)仅由靶向穿刺诊断,62例(66%)由两种方法共同诊断。
  • 系统穿刺检出csPCa-A为29.9%(95%CI 24.3-36.0),靶向穿刺为32.3%(95%CI 26.5-38.4),差异无统计学显著(p=0.38)。
  • 若不做系统穿刺,5.2%(95%CI 2.8-8.7)患者csPCa-A会被漏诊;若不做靶向穿刺,7.6%(95%CI 4.6-11.6)患者会被漏诊。

临床怎么用

  • 作者认为,活检初治患者活检前行多参数MRI可提高临床显著前列腺癌的检出,但似乎不能避免系统穿刺的必要性。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether multiparametric MRI improves the detection of clinically significant prostate cancer and avoids the need for systematic biopsy in biopsy-naive patients remains controversial. We aimed to investigate whether using this approach before biopsy would improve detection of clinically significant prostate cancer in biopsy-naive patients. METHODS: In this prospective, multicentre, paired diagnostic study, done at 16 centres in France, we enrolled patients aged 18-75 years with prostate-specific antigen concentrations of 20 ng/mL or less, and with stage T2c or lower prostate cancer. Eligible patients had been referred for prostate multiparametric MRI before a first set of prostate biopsies, with a planned interval of less than 3 months between MRI and biopsies. An operator masked to multiparametric MRI results did a systematic biopsy by obtaining 12 systematic cores and up to two cores targeting hypoechoic lesions. In the same patient, another operator targeted up to two lesions seen on MRI with a Likert score of 3 or higher (three cores per lesion) using targeted biopsy based on multiparametric MRI findings. Patients with negative multiparametric MRI (Likert score ≤2) had systematic biopsy only. The primary outcome was the detection of clinically significant prostate cancer of International Society of Urological Pathology grade group 2 or higher (csPCa-A), analysed in all patients who received both systematic and targeted biopsies and whose results from both were available for pathological central review, including patients who had protocol deviations. This study is registered with ClinicalTrials.gov, number NCT02485379, and is closed to new participants. FINDINGS: Between July 15, 2015, and Aug 11, 2016, we enrolled 275 patients. 24 (9%) were excluded from the analysis. 53 (21%) of 251 analysed patients had negative (Likert ≤2) multiparametric MRI. csPCa-A was detected in 94 (37%) of 251 patients. 13 (14%) of these 94 patients were diagnosed by systematic biopsy only, 19 (20%) by targeted biopsy only, and 62 (66%) by both techniques. Detection of csPCa-A by systematic biopsy (29·9%, 95% CI 24·3-36·0) and targeted biopsy (32·3%, 26·5-38·4) did not differ significantly (p=0·38). csPCa-A would have been missed in 5·2% (95% CI 2·8-8·7) of patients had systematic biopsy not been done, and in 7·6% (4·6-11·6) of patients had targeted biopsy not been done. Four grade 3 post-biopsy adverse events were reported (3 cases of prostatitis, and 1 case of urinary retention with haematuria). INTERPRETATION: There was no difference between systematic biopsy and targeted biopsy in the detection of ISUP grade group 2 or higher prostate cancer; however, this detection was improved by combining both techniques and both techniques showed substantial added value. Thus, obtaining a multiparametric MRI before biopsy in biopsy-naive patients can improve the detection of clinically significant prostate cancer but does not seem to avoid the need for systematic biopsy. FUNDING: French National Cancer Institute.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2018. PMID: 30470502. doi:10.1016/S1470-2045(18)30569-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。